Ascendia

  MARKET NEWS

Ocean Biomedical Advances Malaria Vaccine Research With New NIH Funding & Expedited Development Pathway
Schrödinger Selects Sapio Sciences to Enhance In Silico Drug Discovery From Plasmid to Structure
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Silexion Therapeutics Reports Strong Tumor Growth Reduction From Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Upperton Completes Build of New Sterile Manufacturing Facility
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio With Issuance of Patent for Platform Technology
Nemera Awarded EcoVadis Gold Medal: A Recognition of its Commitment to Sustainable Development
Alvotech & Teva Announce Filing Acceptance of US Biologics License Applications for a Proposed Biosimilar to Simponi & Simponi Aria
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of Second-Generation TriKE for the Treatment of Hematologic Malignancies
US Patent Office Granted Can-Fite Namodenoson Patent for Use as Anti-Obesity Drug

  EXPERT CONTENT & RESOURCES

On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)

On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)

Dr. Cindy Chung presents a case study demonstrating the development of high concentration bevacizumab suspension at up to 400 mg/mL for suitable subcutaneous delivery of the monoclonal antibody (mAb) therapy. Watch the presentation now to learn more.

ALBA SUCCESS CASE

Container Selection for a Highly Sensitive Drug Product: A Success Story

For new drug products, it is essential that pharmaceutical companies utilize the experience of container suppliers as early as possible.

Premium Cell Culture Ingredients From Actylis

Premium Cell Culture Ingredients From Actylis

Thanks to our many GMP manufacturing sites located in North America, Europe and Asia we can provide the critical ingredients for your Biopharma manufacturing applications.

  FEATURED EDITORIAL

  COMPANY PROFILE

As a global leader in pharmaceutical and medical device testing, Element Materials Technology delivers comprehensive testing solutions that ensure product safety, quality, and regulatory compliance at every stage of development. From initial R&D through commercialization, our 150+ pharmaceutical experts worldwide bring over four decades of experience to your critical projects. Our expertise spans a comprehensive range of specialized capabilities including, but not limited to, biologics testing, Chemical, Manufacturing, and Controls (CMC), biocompatibility assessment, PFAS testing, extractables and leachables studies, and comprehensive antimicrobial and disinfectant analysis. Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR - Enabling Upstream Intensified Bioprocessing

WEBINAR - Enabling Upstream Intensified Bioprocessing

Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on

  WHITEPAPERS & WEBINARS

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

WHITEPAPER - Minimizing API Supply Chain Risks

WHITEPAPER - Minimizing API Supply Chain Risks

By the time your API is brought to a contract manufacturing organization (CMO), you have already put extensive amounts of resources into developing it. It becomes essential that you optimize your API supply chain to be aware of potential risks

…

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

A clear standard for identifying APIs susceptible to Nitrosamine Drug Substance-Related Impurities (NDSRI) formation has been elusive—until now. Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs. Discover how this innovative approach …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 5 – Analytical Testing
February 12 – Injection Devices